AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

医学 拓扑替康 贝伐单抗 危险系数 临床终点 内科学 无进展生存期 化疗 吉西他滨 实体瘤疗效评价标准 临床研究阶段 随机对照试验 肿瘤科 核医学 外科 置信区间
作者
Éric Pujade-Lauraine,Felix Hilpert,Beatrice E. Weber,Alexander Reuß,Andres M. Poveda,Gunnar Balle Kristensen,Roberto Sorio,Ignace B. Vergote,Petronella Oda Witteveen,Aristotelis Bamias,Deolinda Pereira,Pauline Wimberger,Ana Oaknin,Mansoor Raza Mirza,Philippe Follana,David T. Bollag,Isabelle Laure Ray-Coquard,AURELIA Investigators
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:30 (18_suppl): LBA5002-LBA5002 被引量:118
标识
DOI:10.1200/jco.2012.30.18_suppl.lba5002
摘要

LBA5002^ Background: In three phase III trials in OC (2 front line, 1 PT-sensitive recurrent), BEV + CT → BEV significantly improved progression-free survival (PFS) vs CT alone. AURELIA is the first randomized trial of BEV in PT-resistant OC. Methods: Eligible patients (pts) had OC (measurable by RECIST 1.0 or assessable) that had progressed ≤6 mo after ≥4 cycles of PT-based therapy. Pts with refractory OC, history of bowel obstruction, or >2 prior anticancer regimens were ineligible. After CT selection by the investigator (pegylated liposomal doxorubicin [PLD], topotecan [TOP], or weekly paclitaxel [PAC]), pts were randomized to CT either alone or with BEV (10 mg/kg q2w or 15 mg/kg q3w depending on CT) until progression (PD), unacceptable toxicity, or withdrawal of consent. Pts in the CT-alone arm could cross over to BEV monotherapy at PD. The primary endpoint was PFS by RECIST. Secondary endpoints included objective response rate (ORR), overall survival, safety, and quality of life. The design provided 80% power to detect a PFS hazard ratio (HR) of 0.7 with 2-sided log-rank test and α=0.05 after 247 events, assuming median PFS of 4.0 mo with CT and 5.7 mo with CT + BEV. Results: Between Oct 2009 and Apr 2011, 361 pts were randomized to receive selected CT (PLD: 126; PAC: 115; TOP: 120) alone or with BEV. Median follow-up after 301 PFS events was 13.5 mo. Conclusions: In PT-resistant OC, BEV + CT provides statistically significant and clinically meaningful improvement in PFS and ORR vs CT alone. Strict inclusion criteria minimized the incidence of BEV AEs. This is the first phase III trial in PT-resistant OC to show benefit with a targeted therapy and improved outcome with a combination vs monotherapy. [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sxr完成签到,获得积分10
刚刚
li_xingyan发布了新的文献求助10
刚刚
刚刚
冷酷男人完成签到,获得积分10
1秒前
科研通AI6.4的应助被天空采纳,获得10
1秒前
阳光开朗大牛牛完成签到,获得积分10
1秒前
星空发布了新的文献求助10
1秒前
风清扬完成签到,获得积分0
1秒前
小小小先生的应助被mm采纳,获得10
1秒前
Yacfans完成签到 ,获得积分10
1秒前
顶刊刺客cc完成签到,获得积分10
2秒前
2秒前
深情安青的应助被adai007采纳,获得10
2秒前
3秒前
Su完成签到,获得积分10
3秒前
Luoyx完成签到,获得积分10
3秒前
xu完成签到,获得积分10
3秒前
橘子完成签到 ,获得积分10
3秒前
悬停之翼完成签到,获得积分10
3秒前
3秒前
乐观的驳完成签到,获得积分10
3秒前
沉夕完成签到,获得积分10
3秒前
cdercder的应助被元谷雪采纳,获得10
3秒前
落冰花完成签到 ,获得积分20
4秒前
小水蜜桃完成签到 ,获得积分10
4秒前
失物爱发布了新的文献求助10
4秒前
晚秋发布了新的文献求助10
4秒前
俊逸香岚完成签到,获得积分10
4秒前
4秒前
4秒前
爱岗敬业牛马人完成签到,获得积分10
5秒前
飘逸从露完成签到,获得积分10
6秒前
6秒前
Qiancheng完成签到,获得积分10
6秒前
顺利毕业完成签到,获得积分10
6秒前
宋北山完成签到 ,获得积分10
6秒前
优雅醉蓝完成签到,获得积分10
6秒前
酷炫忆梅发布了新的文献求助10
6秒前
乱红完成签到 ,获得积分10
6秒前
Mei烦恼完成签到 ,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105